In a small proof-of-concept study of uncontrolled Graves’ disease, approximately 80% (17/21) of patients who completed a six-month off-treatment follow-up maintained T3/T4 within the normal range after stopping batoclimab, an FcRn-targeting antibody. Among those responders, roughly half (8/17) were in anti-thyroid drug–free remission at six months off therapy; an additional five responders were maintained on low-dose ATD (2.5 mg/day). Safety and tolerability were described as consistent with prior batoclimab studies.
The core development is Immunovant’s use of this off-drug durability signal to underwrite a registrational strategy for its lead FcRn inhibitor, IMVT-1402, in Graves’ disease. The batoclimab study treated patients for 24 weeks with weekly subcutaneous dosing and then followed them off therapy for 24 weeks. The company is currently conducting two global, potentially registrational trials of IMVT-1402, utilizing a 600 mg weekly regimen for up to 52 weeks without a dose step-down. Topline readouts are planned for 2027. The abstract featuring the batoclimab data will be presented at the American Thyroid Association meeting on September 11.
Strategically, Immunovant is positioning FcRn blockade as a mechanism that could suppress hyperthyroidism beyond on-drug control and potentially induce remission off therapy. The move to prosecute registrational trials with IMVT-1402—rather than batoclimab—signals a deliberate asset selection for pivotal work while using the batoclimab dataset to validate the biology in Graves’ disease. The dosing shift to a longer, non–step-down course is an explicit bid to deepen and stabilize the response, addressing the “suboptimal step-down” acknowledged in the batoclimab regimen. For a field long dependent on ATDs, radioactive iodine, or surgery, a durable off-drug biologic outcome would represent a material shift in treatment strategy.
For sites and CROs, the trials target a well-defined but operationally nuanced population: TRAb-positive patients who remain hyperthyroid despite ATD therapy. Protocol execution will hinge on standardized ATD titration rules, frequent thyroid function testing, and clear rescue criteria to preserve endpoint interpretability. Weekly subcutaneous dosing for up to a year increases adherence demands and visit complexity, though it remains feasible across high-volume endocrine centers. Safety surveillance—particularly infection monitoring and immunoglobulin dynamics inherent to FcRn inhibition—will be central to operations and may affect site selection and patient throughput. Payers and health systems will scrutinize off-drug remission rates and durability, given the budget impact of chronic ATD use versus a finite biologic course, and the potential to reduce referrals to radioiodine or surgery.
The immediate question is whether IMVT-1402 can replicate and extend the batoclimab signal with a more intensive regimen and in a larger, controlled setting. Regulators will likely focus on predefined, off-therapy endpoints—normalization of thyroid hormones without ATDs and durability of remission—alongside consistency across TRAb levels and baseline disease severity. Key readouts to watch include relapse curves beyond six months off treatment, the magnitude and kinetics of TRAb reduction, and any differential safety signals with more prolonged exposure. Design details around rescue therapy, ATD tapering algorithms, and stratification by prior disease duration will influence both regulatory credibility and operational complexity. If the registrational program can deliver durable off-drug control with a manageable safety profile, FcRn inhibition could open a new category in Graves’ disease—shifting practice patterns and site workflows toward biologic induction of remission rather than lifelong suppression.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
